“Most users tolerate GLP-1 medications like Ozempic without serious oral health issues, but a subset experience notable side ...

For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy.

Gary Winslett is an associate professor at Middlebury College in Vermont. By now, you’ve probably heard about the weight-loss benefits of GLP-1 drugs like Ozempic (semaglutide) and Mounjaro ...

For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy.

In patients with type 2 diabetes (T2D), treatment with oral semaglutide demonstrated a modest but significant reduction in ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, ...

The Danish drugmaker missed the goal in two phase 3 studies for CagriSema, an investigational combination of amylin analog cagrilintide and GLP-1 drug semaglutide.

And though Hers’s compounded semaglutide is not FDA-approved, she says that every compounded GLP-1 available through the online platform is “made with active pharmaceutical ingredients (APIs ...

That changed with Ozempic, the brand name for semaglutide, Novo Nordisk’s synthetic version of a hormone known as glucagon-like peptide 1, or GLP-1, which helps the body regulate blood sugar levels.

Morley shared: “Novo Nordisk’s oral semaglutide for obesity and Eli Lilly’s orforglipron calcium’s approvals would represent the first oral GLP-1RAs for obesity. “While both products are expected to ...

Weight-loss injections like Mounjaro (tirzepatide) and Wegovy (semaglutide) have gained widespread attention over the past few years as an effective new treatment for weight loss for those living with ...

The market for compounded semaglutide in the U.S. is now roughly “equal” in size to Novo’s own GLP-1 business, the company’s outgoing CEO, Lars Fruergaard Jørgensen, said on a media call ...